BridgeBio Pharma (BBIO) EBIT (2019 - 2025)
Historic EBIT for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$145.2 million.
- BridgeBio Pharma's EBIT rose 2427.69% to -$145.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$609.9 million, marking a year-over-year decrease of 1203.5%. This contributed to the annual value of -$593.0 million for FY2024, which is 237.04% up from last year.
- Latest data reveals that BridgeBio Pharma reported EBIT of -$145.2 million as of Q3 2025, which was up 2427.69% from -$134.3 million recorded in Q2 2025.
- In the past 5 years, BridgeBio Pharma's EBIT registered a high of $343000.0 during Q1 2024, and its lowest value of -$226.0 million during Q4 2024.
- Its 5-year average for EBIT is -$140.7 million, with a median of -$146.1 million in 2023.
- In the last 5 years, BridgeBio Pharma's EBIT soared by 10027.19% in 2024 and then tumbled by 3052915.45% in 2025.
- BridgeBio Pharma's EBIT (Quarter) stood at -$165.6 million in 2021, then rose by 21.97% to -$129.2 million in 2022, then tumbled by 37.28% to -$177.4 million in 2023, then fell by 27.4% to -$226.0 million in 2024, then skyrocketed by 35.76% to -$145.2 million in 2025.
- Its EBIT was -$145.2 million in Q3 2025, compared to -$134.3 million in Q2 2025 and -$104.4 million in Q1 2025.